October 8, 2020
Pam Shang has been appointed vice president for global quality at CrownBioscience The news was announced today.
Pam Shang will be instrumental in further enhancing global quality across the company, leveraging her deep expertise in implementing quality systems for pharma and biotechnology clients including in GLP, GMP and other regulated environments.
Building on CrownBio’s existing platforms, Pam Shang will be responsible for the strategic direction, enhancement, and growth of CrownBio’s quality systems, underlying organizational processes, and leading the associated change management.
“I am excited to welcome Pam to the leadership team,” said Armin Spura, Ph.D., chief executive officer of CrownBio. “With her wealth of experience in implementing global quality systems and overseeing GxP initiatives, Pam will ensure that CrownBio puts quality and our customers at the forefront of all CrownBio initiatives”.
Shang joins CrownBio from Asahi Kasei America, a Japanese pharmaceutical company, where she was head of global quality and compliance. Pam was responsible for all regulatory matters across diverse areas including quality oversight and control, regulatory compliance, and audit management.
CrownBio has seen consistent quality improvements year-on-year, with associated enhanced client satisfaction. The new strategic initiatives led by Mrs. Shang across global operational platforms will ensure high scientific quality and continued dedication to enhance standards and performance across the company.
“I’m delighted to bring my expertise to CrownBio”, said Pam Shang. “The quality of our work and compliance with regulatory standards is extremely important and pivotal for CrownBio’s continued growth. My aim is to ensure that all staff is empowered with proper resources and regulatory knowledge to be successful and accountable, to foster a success-oriented, safe working environment, and to ensure the scientific quality of our products and services”.
Mrs. Shang holds a BS in Management Information Systems and a minor in Business from Southern Illinois University. She also completed a Master’s Program course requirements in Biotechnology at Harvard University.